IP Library Granted Patent US 8,071,302
Granted Patent B2
US 8,071,302 · App. 12/886,016 · Granted Dec 6, 2011

Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,302
App. No.
12/886,016
Granted
Dec 6, 2011
Kind
B2
Abstract

The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Claims (16)

1. A method for determining whether a hepatitis C virus-infected human has an increased risk for developing liver fibrosis, comprising:

a) testing nucleic acid from said human to determine the nucleotide content at a polymorphism as represented by position 101 of SEQ ID NO:8938 or the complement of SEQ ID NO:8938; and

b) correlating the presence of G at position 101 of SEQ ID NO:8938 or C at position 101 of said complement with said human having said increased risk for developing liver fibrosis, or correlating the absence of said G or said C with said human having no said increased risk for developing liver fibrosis.

2. The method of claim 1 , wherein said testing is performed using sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, single-stranded conformation polymorphism analysis, or denaturing gradient gel electrophoresis (DGGE).

3. The method of claim 1 , wherein said nucleic acid is a nucleic acid extract from a biological sample from said human.

4. The method of claim 3 , wherein said biological sample is blood, saliva, or buccal cells.

5. The method of claim 3 , further comprising preparing said nucleic acid extract from said biological sample prior to said testing.

6. The method of claim 5 , further comprising obtaining said biological sample from said human prior to said preparing.

7. The method of claim 1 , wherein said testing comprises nucleic acid amplification.

8. The method of claim 7 , wherein said nucleic acid amplification is carried out by polymerase chain reaction.

9. The method of claim 1 , wherein said testing is performed using an allele-specific method.

10. The method of claim 9 , wherein said allele-specific method detects said G or said C.

11. The method of claim 9 , wherein said allele-specific method is allele-specific probe hybridization, allele-specific primer extension, or allele-specific amplification.

12. The method of claim 9 , wherein said testing is performed using an allele-specific primer comprising SEQ ID NO:34434 or SEQ ID NO:34435.

13. The method of claim 1 , wherein said human is homozygous for said G or said C.

14. The method of claim 1 , wherein said human is heterozygous for said G or said C.